Dalteparin in Preventing DVT in Participants With Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-07

Study Completion Date

2020-06-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients

NCT00041782

Neoplasms Deep Vein Thrombosis

TERMINATED PHASE2

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

NCT05255003

Cancer-associated Thrombosis Thrombocytopenia

RECRUITING PHASE4

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

NCT02585713

Cerebral Vein Thrombosis Deep Vein Thrombosis Gonadal Thrombosis +9 more

COMPLETED PHASE3

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

NCT00876915

Venous Thromboembolism Pulmonary Embolism

TERMINATED PHASE3

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

NCT00216866

Embolism and Thrombosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine the safety of dalteparin as prophylaxis against deep venous thrombosis (DVT) in orthopedic oncology patients.

II. To determine whether there are significantly increased bleeding complications at the surgical site after major oncologic operations in the lower extremity.

OUTLINE:

Participants receive dalteparin subcutaneously (SC) once daily (QD) starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone Sarcoma Femur Fracture Lymphoma Metastatic Neoplasm Pathologic Fracture Plasma Cell Myeloma Soft Tissue Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (dalteparin)

Participants receive dalteparin SC QD starting 12-24 hours after surgery on post-operative day 1 until hospital discharge, about 7-10 days.

Group Type EXPERIMENTAL

Dalteparin

Intervention Type DRUG

Given SC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dalteparin

Given SC

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* GROUP A
* Metastatic disease, myeloma, lymphoma.
* Pathologic fracture or impending pathologic fracture of the femur.
* Intramedullary rod, plating, cementation, hip arthroplasty, or knee arthroplasty.
* GROUP B
* Primary sarcoma of bone or soft tissue of the lower extremity.
* T2 tumor (\> 5 cm by \< 20 cm).
* Radical resection of tumor, which may necessitate major bone or soft tissue reconstruction.

Exclusion Criteria

* Presence of DVT on pre-operative screening ultrasound study.
* Massive tumor (\> 20 cm in greatest dimension).
* Amputation of the affected leg as treatment of tumor.
* Estimated blood loss \> 2 liters during surgery.
* Surgical drain output \> 500 cc of bloody fluid during first 8 hours.
* International normalized ratio (I.N.R.) \> 1.3 pre-operatively or \> 1.5 post-operatively.
* Platelet count \< 100,000 either pre-operatively or post-operatively.
* Indwelling post-operative epidural catheter for pain control.
* History of underlying bleeding disorder, such as hemophilia.
* History of adverse reaction to heparin such as heparin-induced thrombocytopenia.
* Severe liver or renal insufficiency.
* History of hypertensive or diabetic retinopathy.
* History of gastro-intestinal bleeding within 12 months.
* Treatment with warfarin, clopidogrel, aspirin, nonsteroidal antiinflammatory drugs (NSAIDs), low molecular weight heparin (LMWH) or other anti-coagulants for conditions.
* History of stroke.
* Women of child bearing potential having a positive urine or serum pregnancy test (human chorionic gonadotropin \[hCG\]) at the time of pre-operative evaluation (within 7 days of surgery).
* Women who are breastfeeding.
* Hemoglobin \< 8.0 g/dL.
* Platelet count \< 100,000/L.
* Alanine aminotransferase \> 100 IU/L.
* Aspartate aminotransferase \> 100 IU/L.
* Direct bilirubin \> 0.5mg/dL.
* Serum creatinine \> 2.0 mg/dL.
* Patients taking COX-2 inhibitors.
* Patients who have fragmented mechanical heart valves.

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No